Prosecution Insights
Last updated: November 04, 2026
Application No. 18/864,343

THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY DISEASE (MOGAD)

Non-Final OA §112
Filed
Nov 08, 2024
Priority
May 13, 2022 — provisional 63/341,486 +2 more
Examiner
COLEMAN, BRENDA LIBBY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Principia Biopharma Inc.
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
5m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1236 granted / 1652 resolved
+14.8% vs TC avg
Strong +16% interview lift
Without
With
+15.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
47 currently pending
Career history
1699
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
8.5%
-31.5% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
52.7%
+12.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1652 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-11, 16-22, 38 and 39 are pending in this application. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL. —The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 9 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for methylprednisone, does not reasonably provide enablement for corticosteroid generally. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The nature of the instant invention has claims which embrace the compound (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1HI-imidazo[4,5-c]pyridin-2(3H)-one. The method of the instant invention where the compound (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1HI-imidazo[4,5-c]pyridin-2(3H)-one is co-administered a corticosteroid. The specification does not define that which is intended in the use of a “corticosteroid”. The following is a list of corticosteroids: prednisone, prednisolone, dexamethasone, budesonide, fluticasone, hydrocortisone, betamethasone, triamcinolone, bethamethasone, cortisone, ethamethasoneb, fludrocortisone, etc., which includes corticosteroids that are neither supported nor contemplated. This is just a few corticosteroids embraced by the term “corticosteroids”. Claim Objections Claim 10 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Allowable Subject Matter Claims 1-8, 11, 16-22, 38 and 39 are allowed. None of the prior art of record nor a search in the pertinent art area teaches the method of use comprising administering (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1HI-imidazo[4,5-c]pyridin-2(3H)-one as claimed herein. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENDA L COLEMAN whose telephone number is (571)272-0665. The examiner can normally be reached Mon-Fri 10-6 (flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENDA L COLEMAN/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Nov 08, 2024
Application Filed
Aug 24, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778126
MESOIONIC IMIDAZOLIUM COMPOUNDS AND DERIVATIVES FOR COMBATING ANIMAL PESTS
5y 0m to grant Granted Nov 03, 2026
Patent 12780836
PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION
3y 10m to grant Granted Nov 03, 2026
Patent 12778904
HOST DIRECTED DRUG COMBINATIONS FOR TREATMENT OF VIRAL INFECTIONS
2y 11m to grant Granted Nov 03, 2026
Patent 12778921
NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF
3y 0m to grant Granted Nov 03, 2026
Patent 12773415
METHOD FOR TREATING CANCER USING HUMAN MITOCHONDRIAL MALIC ENZYME 2 INHIBITOR
2y 9m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
90%
With Interview (+15.7%)
2y 5m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1652 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month